Journal: Pharmaceuticals

Article Title: From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus ® -Driven Framework for Generic Candesartan Cilexetil Tablets

doi: 10.3390/ph18040562

Figure Lengend Snippet: Prediction results of candesartan American intravenous PBPK model.

Article Snippet: The PBPK model of candesartan cilexetil was developed using commercially available PBPK modeling software GastroPlus ® (version 9.5, Simulations Plus, Inc., Lancaster, CA, USA) and Digit literature data extraction software (version 1.0.4, Simulation Plus, Inc., Lancaster, CA, USA).

Techniques:

Journal: Pharmaceuticals

Article Title: From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus ® -Driven Framework for Generic Candesartan Cilexetil Tablets

doi: 10.3390/ph18040562

Figure Lengend Snippet: PBPK model predictions of 8 mg candesartan cilexetil tablets administered via preprandial oral route across ethnic populations. ( A ) Japanese and ( B ) Chinese.

Article Snippet: The PBPK model of candesartan cilexetil was developed using commercially available PBPK modeling software GastroPlus ® (version 9.5, Simulations Plus, Inc., Lancaster, CA, USA) and Digit literature data extraction software (version 1.0.4, Simulation Plus, Inc., Lancaster, CA, USA).

Techniques:

Journal: Pharmaceuticals

Article Title: From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus ® -Driven Framework for Generic Candesartan Cilexetil Tablets

doi: 10.3390/ph18040562

Figure Lengend Snippet: PBPK-model-predicted pharmacokinetic profiles of 8 mg candesartan cilexetil tablets following fasted oral administration in Chinese.

Article Snippet: The PBPK model of candesartan cilexetil was developed using commercially available PBPK modeling software GastroPlus ® (version 9.5, Simulations Plus, Inc., Lancaster, CA, USA) and Digit literature data extraction software (version 1.0.4, Simulation Plus, Inc., Lancaster, CA, USA).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis

doi: 10.3389/fphar.2025.1555276

Figure Lengend Snippet: Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.

Article Snippet: To assess pharmacokinetics and tissue distribution of vancomycin in PJI patients, we employed the commercially available dynamic PBPK modeling software GastroPlusTM version 9.9 (Simulations Plus, Inc.) to construct a stepwise model as previously described ( ).

Techniques: Concentration Assay, Clinical Proteomics

Journal: Frontiers in Pharmacology

Article Title: High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis

doi: 10.3389/fphar.2025.1555276

Figure Lengend Snippet: The model to predict vancomycin concentrations in the red marrow, yellow marrow and kidney: (A) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the HC group. (B) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the LC group. (C) Observed and PBPK model simulated concentrations in plasma and kidney in the HC group. (D) Observed and PBPK model simulated concentrations in plasma and kidney in the LC group.

Article Snippet: To assess pharmacokinetics and tissue distribution of vancomycin in PJI patients, we employed the commercially available dynamic PBPK modeling software GastroPlusTM version 9.9 (Simulations Plus, Inc.) to construct a stepwise model as previously described ( ).

Techniques: Clinical Proteomics